Covered recipient · General Payments record
KELLY M PRICE
Physician Assistants & Advanced Practice Nursing Providers Nurse Practitioner Family
General Payments · PY2021–2024
$2,836.39
- Reported across 47 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,337.08 | 17 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $323.53 | 7 |
| Acerta Pharma LLC | $313.59 | 3 |
| GlaxoSmithKline, LLC. | $209.15 | 2 |
| Lilly USA, LLC | $133.94 | 1 |
| Madrigal Pharmaceuticals | $131.19 | 1 |
| Phathom Pharmaceuticals, Inc. | $124.99 | 1 |
| ViiV Healthcare Company | $82.55 | 1 |
| Biocon Biologics Inc | $18.14 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $116.66 | 01/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108039589 | CMS |
| ABBVIE INC. | $120.62 | 01/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108039591 | CMS |
| ABBVIE INC. | $16.30 | 03/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108039593 | CMS |
| ABBVIE INC. | $20.80 | 03/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108039595 | CMS |
| ABBVIE INC. | $16.93 | 03/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108039597 | CMS |
| ABBVIE INC. | $16.48 | 08/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108039599 | CMS |
| ABBVIE INC. | $15.74 | 09/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108039601 | CMS |
| AstraZeneca Pharmaceuticals LP | $128.84 | 02/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105564718 | CMS |
| AstraZeneca Pharmaceuticals LP | $114.30 | 03/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105836365 | CMS |
| AstraZeneca Pharmaceuticals LP | $70.45 | 05/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104327154 | CMS |
| Biocon Biologics Inc | $18.14 | 03/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1154784012 | CMS |
| GlaxoSmithKline, LLC. | $119.70 | 06/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116587083 | CMS |
| GlaxoSmithKline, LLC. | $89.45 | 09/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116054048 | CMS |
| Lilly USA, LLC | $133.94 | 03/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135773562 | CMS |
| Madrigal Pharmaceuticals | $131.19 | 10/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1144197263 | CMS |
| Phathom Pharmaceuticals, Inc. | $124.99 | 05/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151198119 | CMS |
| ViiV Healthcare Company | $82.55 | 04/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1112720994 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.